Enzon Spins Off R&D Company With $150 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Specialty pharma keeps Enzon name; Icahn gets his way.
You may also be interested in...
Enzon Hunkers Down, Canceling Spin-Out To Guard Cash
Early-stage pipeline could garner licensing deals as clinical work proceeds, with peak burn year ahead.
Enzon Hunkers Down, Canceling Spin-Out To Guard Cash
Early-stage pipeline could garner licensing deals as clinical work proceeds, with peak burn year ahead.
UCB Wins FDA Nod For Cimzia In Crohn’s
Application is pending in rheumatoid arthritis, too.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: